Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from December 2022.
Intellectual Property
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Biotech Companies Are Opening Manufacturing Sites in Africa: Will This Help Vaccine Equity? Biotech Companies Are Opening Manufacturing Sites in Africa: Will This Help Vaccine Equity?
If pharma giants truly are committed to addressing vaccine inequity, just building manufacturing capacity in Africa might not be enough.
-
Read more: COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues
An explanation of the key patents at stake in the intellectual property dispute between Moderna and Pfizer/BioNTech over COVID-19 vaccines.
-
Read more: The Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA The Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA
The future of public health in an “RNA world” is on trial in a trade secrecy dispute worth $950 million.
-
Read more: The ‘Res Nullius’ Construction of Human Genomic Data The ‘Res Nullius’ Construction of Human Genomic Data
When DNA is sequenced and genomic data are generated, a legal object comes into being.
-
Read more: What Happened to the COVID-19 Vaccine Patent Waiver? What Happened to the COVID-19 Vaccine Patent Waiver?
The negotiations leading to the WTO Decision proved once again the inadequacy of the debate over intellectual property rights.
-
Read more: Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’ Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’
COVID-19 vaccine manufacturers refusing to share samples may be the latest example of the tragedy of the “anticommons” in biomedical research.
-
Read more: We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy
Biden’s new initiative takes an expansive view of the roles of biotechnology and biomanufacturing in the United States economy.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from August 2022.
-
Read more: Proposed Amendments Would Make Foreign Investment in India’s Biological Resources Easier Proposed Amendments Would Make Foreign Investment in India’s Biological Resources Easier
Indian lawmakers are currently debating amendments that would make it easier for foreign investors to develop products from native biological resources.
